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Imaging of MSC transplantation in neuroscience
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Due to their stemness and unique paracrine, 
immunomodulatory and anti-inflammatory properties, 
Mesenchymal Stem Cells (MSCs) hold great promise 
for tissue regeneration and wound repair, as well as for 
the treatment of autoimmune disorders, tumors and 
cerebrovascular diseases. Notably, their relevance as 
potential therapeutic agents for nervous system diseases/
lesions (including stroke, neurodegeneration, neuropathy, 
and traumatic damage) is also considerably increasing [1, 
2]. Specifically, aiming at enhancing the cell/fiber rescue 
and the functional recovery, the MSC transplantation 
represents a promising therapeutic approach after serious 
traumatic events such as Spinal Cord Injury (SCI), that 
often lead to seriously disabling consequences [3]. Many 
key factors can influence the success of a cell therapy, 
including the origin of the cell population (allogenic 
vs autologous), the graft size, the administration route, 
the homing efficiency and the host environment. As 
a consequence, the opportunity to obtain spatial and 
temporal information on the graft distribution appears 
crucial [4]. The in vivo tracking of MSCs migration and 
biodistribution can be pursued using several clinical 
imaging techniques such as NIRF imaging, PAI, PET, 
SPECT, and MRI, and it is typically accomplished through 
the in vitro labelling of cells with a specific contrast 
agent. This method assures a non-invasive time-stratified 
analysis in living models, preserving the integrity of target 
organs and avoiding the animal sacrifice. Despite the good 
clinical potential showed by this approach, some common 
challenges remain, including the possibility of long-term 
monitoring, cytotoxicity, poor labeling efficiency, probe 
degradation, and difficult delivery of contrast to certain 
anatomic districts, such as the central nervous system 
(CNS). 
As cell tracking experiments requires a good spatial 
resolution, MRI is certainly one of the preferred options. 
So far, the most used class of cell-labelling MRI agent 
is represented by the iron oxide nanoparticles (IONs) 
whose potential has been already demonstrated in some 
completed clinical trials aimed at tracking inflammatory 
or dendritic cells [5]. However, it has to be noticed that 
IONs-labeled cells appear as hypointense spots on T2- and 
T2
*-weighted MR images, thus making sometimes difficult 
to discern them into anatomic areas with a low intrinsic 
MRI signal, as in micro-hemorrhage, or micro air bubbles 
commonly present after the surgery post-SCI. Moreover, 
besides being frequently affected by blooming artifacts, 
IONs are associated with dose-dependent cytotoxic 
phenomena, such that the high doses needed for successful 
labelling entail an acknowledged risk of compromising 
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the cellular survival. These potential drawbacks can be 
overcome using the most commonly used class of clinical 
MRI agents based on paramagnetic Gd-based complexes. 
These chemicals produce bright spots on T1-weighted 
MRI and include molecules provided with extremely high 
thermodynamic and kinetic stability, hydrophilic character, 
small size, and biological inertness. Nevertheless, 
clinically-approved Gd-based agents cannot compete with 
IONs in terms of contrast detection sensitivity, and they 
still represent a challenging implementation in the field of 
imaging MSCs graft.
An important step forward to bridge the gap 
between Gd-based agents and IONs for in vivo cellular 
imaging has been recently achieved, allowing the cytosolic 
entrapment of high amount of the clinically approved MRI 
agent Gadoteridol (marketed as ProHance™) through a 
novel cell labelling procedure based on osmotic shock [6]. 
The escape from the endocytic internalization pathway is 
very crucial for enhancing the sensitivity in the detection 
of the bright contrast because the endosomal entrapment 
of the labelling agent is inevitably accompanied by 
a “quenching” of the T1 contrast [6]. Based on our 
experience, we argued that this labelling procedure could 
be helpful in tracking the migration of “therapeutic” 
MSCs in a murine SCI model (hemisection) [7]. Indeed, 
in addition to ascertain improvements in both cellular 
uptake and sensitivity in contrast detection in vitro, we 
found that the monitoring of MSCs migratory dynamics in 
vivo was feasible for about 10 days. By implanting MSCs 
about 1 mm caudally to spinal lesion site (as shown in 
the Figure below), it was possible to observe a migratory 
stream of cells progressively reaching the injured area 
in about 7 days. Moreover, the absence of alterations in 
the biological and functional profile of MSCs after the 
labeling step was verified in vitro, and confirmed in vivo 
by the evident motor recovery shown by treated animals, 
thus indicating the unaltered therapeutic efficacy of cells. 
In the context of experimental research, this efficient, safe, 
reliable, and simple labeling technique may serve to (i) 
test and compare different transplantation protocols, (ii) 
dynamically assess cell distribution, (iii) correlate the 
beneficial effects of the cell graft (estimated by behavioral 
tests) to the MRI observations, and (iv) analyze the ability 
of the injected cells to move in response to chemotactic 
stimuli in vivo and in real-time. Due to the relatively 
limited persistence of the contrast, the translational 
significance of such technique appears restricted to the 
early assessment of cell survival during the first days 
after injection, whose relevance however should not be 
underestimated considering that the detrimental response 
of the host CNS to the graft can determine death of 
exogenous cells within the first hours after transplantation 
[8].
In conclusion, the hypotonic labeling with positive 
MRI CAs represents a significant technical improvement 
in preclinical imaging of MSCs as applied to murine SCI, 
being potentially valid also in larger animals and humans, 
and lays the basis to address the current challenges 
imposed by the complexity of the CNS and the specific 
medical requirements of the stem cell-based therapies.
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